Regenxbio (NASDAQ:RGNX) was upgraded by equities researchers at BidaskClub from a “buy” rating to a “strong-buy” rating in a note issued to investors on Friday, December 22nd.
A number of other research analysts have also issued reports on the company. Chardan Capital restated a “buy” rating and set a $75.00 price objective (up previously from $55.00) on shares of Regenxbio in a research report on Tuesday, September 5th. Zacks Investment Research upgraded Regenxbio from a “hold” rating to a “strong-buy” rating and set a $38.00 price target for the company in a research report on Wednesday, October 18th. Morgan Stanley reiterated an “overweight” rating and set a $34.00 price target on shares of Regenxbio in a research report on Thursday, November 9th. Barclays began coverage on Regenxbio in a research report on Wednesday, November 22nd. They set an “overweight” rating and a $38.00 price target for the company. Finally, Bank of America reiterated a “buy” rating and set a $38.00 price target (up previously from $33.00) on shares of Regenxbio in a research report on Monday, October 9th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company’s stock. Regenxbio currently has a consensus rating of “Buy” and a consensus target price of $42.43.
Shares of Regenxbio (RGNX) traded up $0.55 on Friday, hitting $30.45. The stock had a trading volume of 642,016 shares, compared to its average volume of 465,068. The firm has a market cap of $931.24, a price-to-earnings ratio of -11.28 and a beta of -0.88. Regenxbio has a one year low of $16.30 and a one year high of $36.45.
Regenxbio (NASDAQ:RGNX) last issued its earnings results on Wednesday, November 8th. The biotechnology company reported ($0.67) EPS for the quarter, topping the consensus estimate of ($0.71) by $0.04. Regenxbio had a negative return on equity of 39.33% and a negative net margin of 764.06%. The company had revenue of $1.34 million during the quarter. research analysts anticipate that Regenxbio will post -2.71 earnings per share for the current fiscal year.
In other news, CFO Vittal Vasista sold 5,000 shares of Regenxbio stock in a transaction on Monday, October 16th. The stock was sold at an average price of $33.25, for a total transaction of $166,250.00. Following the transaction, the chief financial officer now owns 92,283 shares in the company, valued at $3,068,409.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Kenneth T. Mills sold 10,000 shares of Regenxbio stock in a transaction on Monday, November 20th. The shares were sold at an average price of $27.71, for a total value of $277,100.00. The disclosure for this sale can be found here. Insiders have sold 94,000 shares of company stock worth $2,947,446 over the last ninety days. 17.00% of the stock is owned by insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of RGNX. Schwab Charles Investment Management Inc. grew its stake in Regenxbio by 6.2% in the first quarter. Schwab Charles Investment Management Inc. now owns 73,724 shares of the biotechnology company’s stock valued at $1,423,000 after purchasing an additional 4,275 shares in the last quarter. Rhumbline Advisers grew its stake in Regenxbio by 45.5% in the second quarter. Rhumbline Advisers now owns 27,251 shares of the biotechnology company’s stock valued at $538,000 after purchasing an additional 8,520 shares in the last quarter. State of Wisconsin Investment Board purchased a new position in Regenxbio in the second quarter valued at about $415,000. Bank of New York Mellon Corp grew its stake in Regenxbio by 21.0% in the second quarter. Bank of New York Mellon Corp now owns 177,277 shares of the biotechnology company’s stock valued at $3,501,000 after purchasing an additional 30,725 shares in the last quarter. Finally, Legal & General Group Plc grew its stake in Regenxbio by 41.4% in the second quarter. Legal & General Group Plc now owns 6,870 shares of the biotechnology company’s stock valued at $137,000 after purchasing an additional 2,011 shares in the last quarter. Hedge funds and other institutional investors own 68.73% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This report was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another website, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The legal version of this report can be read at https://www.dispatchtribunal.com/2018/01/13/regenxbio-rgnx-upgraded-to-strong-buy-at-bidaskclub.html.
Regenxbio Company Profile
REGENXBIO Inc is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases.
Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.